Management of Chronic Liver Disease

Treatment of Underlying Causes

The American Association for the Study of Liver Diseases recommends identifying and treating the underlying cause of chronic liver disease, which can potentially reverse early cirrhosis and prevent progression to end-stage liver disease 1, 2, 3
Lifestyle modification, including weight loss, dietary changes, physical exercise, and discouraging alcohol consumption, is the primary intervention for Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 1
Incretin-based therapies, such as semaglutide and tirzepatide, should be used for patients with type 2 diabetes or obesity with additional metabolic risk factors 1
Bariatric surgery is an option for patients with MASLD and obesity 1
Resmetirom should be considered for adults with non-cirrhotic MASH and significant liver fibrosis (stage ≥2) 1
Case-finding strategies using non-invasive tests, such as FIB-4 score followed by transient elastography, should be applied in individuals with cardiometabolic risk factors, abnormal liver enzymes, or radiological signs of hepatic steatosis 1

For hepatitis B with compensated cirrhosis, the American Association for the Study of Liver Diseases recommends initiating entecavir 0.5 mg daily or tenofovir when HBV DNA ≥2,000 IU/mL regardless of ALT levels 2
For hepatitis C, direct-acting antivirals (DAAs) can improve liver function and reduce portal hypertension, with minimal side effects and high cure rates 1, 4, 3
Monitor HCV RNA at weeks 4, 8, and 12-24 of treatment depending on the regimen 5

Complete cessation of alcohol consumption is mandatory and may lead to "re-compensation" and improved outcomes 2, 3
Avoid all alcohol intake, as even moderate consumption can accelerate disease progression 1

First-line treatment for ascites consists of sodium restriction (88 mmol/day or 2 grams/day) and diuretic therapy with spironolactone 100 mg daily, with or without furosemide 40 mg daily 2
Fluid restriction is not necessary unless serum sodium is less than 120-125 mmol/L 2
For tense ascites, perform initial therapeutic paracentesis (removing 4-6 liters) followed by sodium restriction and diuretic therapy 2
Avoid NSAIDs completely, as they reduce urinary sodium excretion and can convert diuretic-sensitive ascites to refractory ascites 2

Initiate vasoactive drugs (terlipressin, octreotide, or somatostatin) immediately upon suspicion, even before endoscopic confirmation 2
Start antibiotic prophylaxis immediately in all cirrhotic patients with GI bleeding (ceftriaxone 1 gram daily for 7 days) 2
Perform endoscopic band ligation within 12 hours of admission once hemodynamic stability is achieved 2
Use a restrictive transfusion strategy with a hemoglobin threshold of 7 g/dL, targeting 7-9 g/dL 2
TIPS should be used as rescue therapy for persistent bleeding or early rebleeding 2

Lactulose is first-line therapy, reducing mortality (8.5% vs 14%) and recurrent overt hepatic encephalopathy (25.5% vs 46.8%) 6
Identify and treat precipitating factors: infection, GI bleeding, constipation, electrolyte abnormalities, and medications 6, 2
Ensure adequate protein intake (1.2-1.5 g/kg/day) to prevent sarcopenia, which worsens hepatic encephalopathy 6

Perform ultrasound with or without alpha-fetoprotein every 6 months in all patients with cirrhosis 4, 7
Continue surveillance even after achieving sustained virologic response (SVR) in viral hepatitis, as HCC risk persists 5, 4, 7
Screen for varices by endoscopy at the time of cirrhosis diagnosis 2
Repeat endoscopy every 1-3 years depending on the size of varices and degree of liver dysfunction 2
Reassess fibrosis using non-invasive tests after 3 years in patients who remain at risk 8
Extend the interval to 5 years in patients with no risk factors for progression who achieve weight loss goals 8

Educate patients about salt restriction (2 grams/day), medication adherence, and recognition of warning signs (confusion, abdominal distension, black stools, jaundice) 2, 3
Provide written materials and involve caregivers in education sessions 6
Consider telemedicine and remote monitoring technologies to improve outcomes and reduce hospital readmissions 9, 3